biproxi, Inc. – Trademark Portfolio
Entity Type: 03
biproxi, Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 5 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include B, BIPROXI, and BIPROXIMATE. The owner is based in Burlingame, CA.
1325 Howard Ave., Suite 338
Burlingame, CA 94010
Showing of trademarks Trademarks
Trademark Classifications
biproxi, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does biproxi, Inc. have?
biproxi, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 abandoned.
What trademark classes does biproxi, Inc. file in?
biproxi, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 35 (Advertising & Business). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are biproxi, Inc.'s most well-known trademarks?
biproxi, Inc.'s registered trademark portfolio includes well-known marks such as B, BIPROXI, and BIPROXIMATE. These are among 3 currently registered trademarks in the portfolio.
What is biproxi, Inc.'s trademark registration success rate?
biproxi, Inc. has a 43% trademark registration rate, with 3 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.